share_log

康哲藥業:翌日披露報表

CMS: Next Day Disclosure Return

Hong Kong Stock Exchange ·  Apr 15 07:56
Summary by Moomoo AI
康哲藥業控股有限公司(CMS)於2024年4月2日至4月15日期間,進行了多次股份購回但未註銷,總計購回股份數目達到10,350,000股,佔已發行股份的0.4221%。根據最新一次購回活動於2024年4月15日,公司在香港聯合交易所購回1,050,000股,每股價格介於HKD 7.04至HKD 7.16之間,總付出金額為HKD 7,444,020。該系列股份購回活動已獲得公司董事會的正式授權批准,並符合香港聯合交易所有限公司證券上市規則的相關規定。
康哲藥業控股有限公司(CMS)於2024年4月2日至4月15日期間,進行了多次股份購回但未註銷,總計購回股份數目達到10,350,000股,佔已發行股份的0.4221%。根據最新一次購回活動於2024年4月15日,公司在香港聯合交易所購回1,050,000股,每股價格介於HKD 7.04至HKD 7.16之間,總付出金額為HKD 7,444,020。該系列股份購回活動已獲得公司董事會的正式授權批准,並符合香港聯合交易所有限公司證券上市規則的相關規定。
During the period from April 2 to April 15, 2024, Conge Pharmaceutical Holdings Limited (CMS) made several share repurchases but were not written off. The total number of repurchases reached 10,350,000 shares, representing 0.4221% of the issued shares. Based on the most recent repurchase activity on 15 April 2024, the Company repurchased 1,050,000 shares on the Hong Kong Stock Exchange at a price between HKD 7.04 and HKD 7.16 for a total payment of HKD 7,444,020. This series of share repurchases has been formally authorised by the Company's Board of Directors and complies with the relevant provisions of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
During the period from April 2 to April 15, 2024, Conge Pharmaceutical Holdings Limited (CMS) made several share repurchases but were not written off. The total number of repurchases reached 10,350,000 shares, representing 0.4221% of the issued shares. Based on the most recent repurchase activity on 15 April 2024, the Company repurchased 1,050,000 shares on the Hong Kong Stock Exchange at a price between HKD 7.04 and HKD 7.16 for a total payment of HKD 7,444,020. This series of share repurchases has been formally authorised by the Company's Board of Directors and complies with the relevant provisions of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more